目的:EGFR-TKI治疗曾经有效的NSCLC患者,在TKI治疗失败后再次选用TKI治疗仍有部分患者可再次临床获益。本文通过回顾性研究验征再服T KI的疗效,并力图发现与再服TKI疗效有关的临床因素,以及两次TKI治疗的间隔期是否影响再服TKI的疗效。方法:2003年3月～2012年3月经治的40例初始TKI治疗失败后再服TKI的NSCLC患者,分析其临床因素与再服TKI治疗PFS的相关性。结果:全组患者自初始TKI治疗起中位生存期为29个月(95%CI:21.67～36.33),自再次TKI治疗起中位生存期为13个月(95%CI:8.65～17.35)全组再服TKI治疗的中位PFS为2个月(1～2个月),疾病控制率为50%。两次TKI治疗间歇期长于1、2、3个月组再服TKI治疗的PFS相比相应的不足1、2、3个月组无统计学差异(P>0.05),间歇期进行化疗组再服TKI的中位PFS短于未化疗组,但差异无统计学意义(1个月vs.4个月,P=0.650)。结论:初始TKI治疗有效的患者,再次使用TKI类药物仍有部分患者可达到临床获益再次使用TKI治疗的疗效与两次T KI治疗间的间歇期长短无关,与间歇期是否进行过化疗也无关 PURPOSE: EGFR-TKI therapy was once effective in patients with NSCLC, TKI treatment again after the failure of TKI treatment, there are still some patients can once again clinically benefit. In this review, we retrospectively evaluated the efficacy of TKI for further trials and sought to find out the clinical factors associated with the efficacy of TKI treatment and whether the interval between two TKI treatments affected the efficacy of TKI. Methods: From March 2003 to March 2012, 40 patients with initial NSCLC treated with TKI after failure of initial TKI treatment were enrolled. The correlation between clinical factors and PFS after TKI treatment was analyzed. RESULTS: The median overall survival for all patients was 29 months (95% CI: 21.67 to 36.33) since initial TKI treatment and 13 months (95% CI: 8.65 to 17.35) after re-TKI treatment The median overall PFS for second-serve TKI was 2 months (1 to 2 months) with a disease control rate of 50%. There was no significant difference in PFS between two TKI treatment periods longer than 1,2,3 months group and TKI treatment (P> 0.05) Median PFS was shorter for TKI than for non-chemotherapy group, but the difference was not statistically significant (1 month vs. 4 months, P = 0.650). CONCLUSIONS: Patients with initial TKI therapy who are re-used with TKIs may still achieve clinical benefit. The efficacy of re-using TKI has nothing to do with the duration of the intermission between two TKI treatments, and is chemotherapy with intermittent Nothing to do